Third-Party Tested ≥98% HPLC Purity — USA Shipped

10 Products

Metabolic & Incretin Pathway

Research peptides targeting GLP-1, GIP, glucagon, and amylin receptors for metabolic-pathway studies.

About Metabolic & Incretin Pathway Research Peptides

This collection covers incretin and metabolic-pathway research peptides: triple-agonist compounds targeting GIP, GLP-1, and glucagon receptors, synthetic amylin analogues, and GHRH fragments, plus 5-Amino-1MQ, a small-molecule NNMT inhibitor studied in cellular-energy and NAD+ pathway research. Compounds are studied in glucose-regulation, insulin-signaling, and lipid-metabolism models. Every item is third-party tested to ≥98% HPLC purity and shipped lyophilized from our US facility. For laboratory research use only.

Metabolic & Incretin Pathway — Frequently Asked Questions

What compounds are in the metabolic and incretin category?

This collection covers triple-agonist compounds targeting GIP, GLP-1 and glucagon receptors, synthetic amylin analogues, GHRH fragments, and 5-Amino-1MQ, a small-molecule NNMT inhibitor studied in cellular-energy and NAD+ pathway work. All are supplied as lyophilized powder for laboratory research use only.

What research models are incretin peptides studied in?

Laboratories study these compounds in glucose-regulation, insulin-signaling and lipid-metabolism models. Published receptor-binding and pathway data support in-vitro and preclinical characterization. They are not approved for human or veterinary use.

What purity standard do these compounds meet?

Every compound is third-party tested to a minimum 98% HPLC purity benchmark, with identity confirmed by mass spectrometry. A lot-specific certificate of analysis ships with each order and past certificates are published in the public COA library.

Browse Other Categories